Surgical staging of uterine cancer: an analysis of perioperative morbidity.
Surgical staging documented extrauterine disease in 27.9% of 168 patients with apparent early-clinical-stage uterine cancer. An analysis of operative time (78 +/- 21 min), blood loss (332 +/- 160 cc), and surgical site infection risks (4.7%) indicated little additional risk of lymphadenectomy. The long-term risk of lymphocyst (1.3%) or lymphedema (0.7%) was small. The histologic information obtained from staging was utilized to rationally guide the need for adjunctive teletherapy. The overall risk of recurrence (median follow-up, 26 months) with surgical Stage I disease was 2.6%.
Orr
J W
JW
Department of Gynecology and Obstetrics, Watson Clinic, Lakeland, Florida 33805.
Holloway
R W
RW
Orr
P F
PF
Holimon
J L
JL
D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007044:Hysterectomy / Q000379:methods; D007432:Intraoperative Period; D008197:Lymph Node Excision; D009017:Morbidity; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D011183:Postoperative Complications; D011184:Postoperative Period; D013529:Surgical Wound Dehiscence; D013530:Surgical Wound Infection; D014594:Uterine Neoplasms / Q000453:epidemiology / Q000473:pathology / Q000601:surgery*